<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701698</url>
  </required_header>
  <id_info>
    <org_study_id>SHSYXY-Ruxo-GVHD-2018001</org_study_id>
    <nct_id>NCT03701698</nct_id>
  </id_info>
  <brief_title>Ruxolitinib and Steroid as First Line Therapy for Acute GVHD</brief_title>
  <official_title>Ruxolitinib and Methylprednisolone as First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with
      methylprednisolone as first line therapy in patients with Grades II to IV acute
      graft-versus-host disease (GVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment:

      Once patients are diagnosed with grade II~IV acute GVHD, the combination therapy should be
      initiated as soon as possible.

        1. Methylprednisolone: 2mg/kg/d, iv or iv gtt, in two or three divided doses. Taper steroid
           every one or two weeks according to patient's response.

        2. Ruxolitinib 5~10mg bid po for at least 28 days. If patient's ANC&lt;0.5×10e9/L or PLT&lt;
           20×10e9/L, cease ruxolitinib until recovery of ANC higher than 0.5×10e9/L or PLT higher
           than 20×10e9/L.

      Indication for stopping Ruxolitinib treatment:

        1. No response after ruxolitinib treatment for 28 days.

        2. Develop life-threatening complication.

        3. ANC&lt;0.5×10e9/L or PLT&lt; 20×10e9/L.

      Indication for second line acute GVHD treatment:

        1. deterioration of acute GVHD in 3 days

        2. no response after 7 days

        3. no complete remission after 2 weeks.

      Suggestions of second line therapy:

      Basiliximab 20mg, d1, d4, d8.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>overall response rate of acute GVHD treatment, including complete response rate and partial response rate after combination therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to response</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>days from beginning to the first day of maximum response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reactivation rate of cytomegalovirus</measure>
    <time_frame>100 days within transplant</time_frame>
    <description>reactivation rate of cytomegalovirus infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year incidence of chronic GVHD</measure>
    <time_frame>1 year within transplant</time_frame>
    <description>incidence of chronic GVHD 1 year after transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute GVHD</condition>
  <arm_group>
    <arm_group_label>combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.
Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
Ruxolitinib oral tablet, 5~10mg bid orally, for at least 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib Oral Tablet</intervention_name>
    <description>Ruxolitinib Oral Tablet （Jakafi）, 5~10mg bid po for at least 28 days.</description>
    <arm_group_label>combination therapy</arm_group_label>
    <other_name>Jakafi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.</description>
    <arm_group_label>combination therapy</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosed with hematological diseases.

          2. recipients of allogeneic peripheral blood stem cell transplantation.

          3. new onset of grade II~IV acute graft versus host disease within 100 days
             post-transplantation.

        exclusion criteria:

          1. recipients of second allogeneic stem cell transplant.

          2. acute GVHD induced by donor lymphocyte infusion, interferon.

          3. received treatment other than steroid before enrollment.

          4. overlap GVHD syndrome.

          5. pregnant or breast-feeding women.

          6. absolute neutrophil count (ANC) &lt;0.5×10e9/L or platelet count (PLT) &lt; 20×10e9/L

          7. non-GVHD related liver dysfunction: glutamic pyruvic transaminase&gt;= 4 times of upper
             normal limit, direct bilirubin &gt;= 4 times of upper normal limit

          8. renal dysfunction: creatinine clearance &lt; 15 mL/min or glomerular filtration rate&lt; 15
             mL/min

          9. uncontrolled infection

         10. human immunodeficiency virus infection

         11. active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.

         12. relapse of primary malignant hematological diseases, or graft rejection.

         13. allergic history to Janus kinase inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianmin Song, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liping Wan, M.D.</last_name>
    <phone>86-21-37798987</phone>
    <email>lipingwan@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jieling Jiang, M.D.</last_name>
    <phone>86-21-37798987</phone>
    <email>Jiangjieling66@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xianmin Song, MD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

